Huberman is joining Hims as a non-independent board member, guiding science and marketing.
Terms. Per an SEC filing, the deal could bank Huberman up to $24M plus board comp ($50K cash + $250K equity annually). That includes $7M for two years of advisory, $15M to Scicomm Media for three years of podcast ads, and up to $1M annually for optional short-form videos.
Underperforming by Wall Street’s standards, Hims’ revenue rose 49% YoY in Q3, but it reported a net loss of $33M, sending its stock and 2026 forecast down.
Logic. Aligning with Hims CEO Andrew Dudum’s goal of democratizing personalized healthcare for “the middle 95%,” Huberman initiated the relationship — with Hims’ ownership of end-to-end, US-based peptide manufacturing a major selling point.
The platform is prepping the rollout of sermorelin, glutathione, B12, NAD+, and L-carnitine, with BPC-157 and TB-500 to follow when allowed.
Strategy. Stoking agency to distinguish from Big Pharma, DTC health ads veer unhinged, with peptide sellers using pointed vibes to woo consumers. Focused on GLP-1s, Ro signed Charles Barkley and Serena Williams as ambassadors, using their athletic history to challenge stigma.
Takeaway: Making marketing ubiquitous, companies want to normalize peptides as an entry point to next-gen care — steering messaging away from biohacking and toward basic health.
